Data on the responses of neurons and astrocytes to oxidative injury in the presence of insulin-like growth factor I

Fig1a) Neuron viability measured as percentage of GFP positive cells cultured ± astrocytes after treatment with H2O2. N: neurons, NA: neurons + astrocytes. Names for each file refer to the related figures in the associated research article.

Fig1b) IGF-I measured in the supernatant of neuron or astrocyte cultures treated ± with H2O2.

Fig1c) pAKT levels measured in astrocytes transfected with an IGF-IR dominant negative construct (IGF-IR DN) after treatment with IGF-I.

Fig1d) Neuron viability measured as percentage of GFP positive cells cultured with astrocytes transfected with IGF-IR DN.

Fig2a) pAKT levels in astrocytes treated ± with PPP (picropodophyllin) after treatment with IGF-I.

Fig2b) Neuron viability measured as percentage of GFP positive cells treated ± with PPP and H2O2.

Fig2c) Neuron viability expressed as percentage of GFP positive cells cultured with astrocytes and treated ± with PPP and H2O2.

Fig2d) Neuron viability measured as percentage of GFP positive cells cultured with astrocytes (both cells types from forebrain) and treated ± with PPP and H2O2.

Fig2e) Neuron viability measured as percentage of GFP positive cells cultured with astrocytes and treated with IGF-I, H2O2 or both.

Fig3a) Neuron death measured as percentage of PI positive cells treated ± with IGF-I and H2O2.

Fig3b) Astrocyte survival expressed as percentage of PI negative cells treated ± with IGF-I and H2O2.

Fig3c) FOXO activity from astrocytes treated with IGF-I, H2O2 or both.

Fig3d) Cell survival expressed as percentage of GFP positive cells for astrocytes transfected with wt or AKT-insensitive mutant FOXO, treated ± with IGF-Iand H2O2.

Fig3e) pAKT levels form astrocytes treated with IGF-I I ± H2O2.

Fig4a) Mitochondrial O2- measured in astrocytes treated ± with IGF-I and H2O2.

Fig4b) Total ROS (reactive oxygen species) measured in astrocytes treated ± with IGF-I and H2O2.

Fig5a) Cu/Zn SOD (superoxide dismutase) levels from astrocytes treated with IGF-I, H2O2 or both.

Fig5b) Mn SOD levels from astrocytes treated with IGF-I, H2O2 or both.

Fig6a) TXNIP levels from astrocytes treated with IGF-I, H2O2 or both.

Fig6b) Cell survival from astrocytes transfected with TXNIP shRNA ± H2O2.

Fig6c) TXNIP levels from neurons treated with IGF-I, H2O2 or both.

Fig6d) TXNIP levels from astrocytes pre-treated with the calcium inhibitor BAPTA in the presence of IGF-I, H2O2 or both.

Fig7a) SCF (stem cell factor) mRNA from astrocytes treated with IGF-I, H2O2 or both.

Fig7b) Neuron viability measured as percentage of GFP positive cells treated with IGF-I, SCF or both in the presence of H2O2.

Fig7c) pERK levels form astrocytes treated with IGF-I, SCF or both ± H2O2.

Fig7d) SCF and IGF-I mRNA from control or MCAO (medial cerebral artery occlusion) animal cortex (contralateral or ispsilateral cortex).

Fig7e) SCF protein levels from control or MCAO animal cortex (contralateral or ispsilateral cortex).

Luminol) Reactive oxygen species (ROS) measurements using luminol (which detects superoxide anions)